Multidisciplinary | Home

Malaysia
Search
Sign In

Multidisciplinary Search

Multidisciplinary

Multidisciplinary

Home News Diseases Conferences Special Reports Multimedia

Apalutamide plus ADT improves PFS2 in mCSPC

Roshini Claire Anthony, 10 hours ago

The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.

Inadequate health literacy leads to adverse maternal, neonatal outcomes

10 hours ago

Poor health literacy in nulliparous women who are engaged in early prenatal care often leads to adverse maternal and neonatal outcomes, according to a study, adding that this must be considered a social determinant of perinatal health.

Updates from DECLARE-TIMI 58: Dapagliflozin offers cardiorenal benefit across the board in patients with T2DM

26 Feb 2020

At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.

CVOTs reinforce linagliptin’s cardiorenal safety profile in the management of T2D

24 Feb 2020

In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).

Doing it right from the get-go: The commitment of Sunway Medical Centre Velocity towards patient safety and satisfaction

Pank Jit Sin, 28 Jan 2020

The interest in healthcare and medicine is evident from companies in fields unrelated to healthcare venturing into the scene. With this interest is the boom of healthcare facilities, both clinics and hospitals, being set up in the country. As of end 2017, Malaysia counted 200 private hospitals with 14,799 beds. [https://www.export.gov/article?id=Malaysia-Healthcare, Accessed on 18 November]

The recent launch of Sunway Medical Centre Velocity (SMCV) coincides with the boom of hospitals established in the country. However, its founding should not be seen as jumping on the bandwagon. Rather, the hospital is a carefully planned and executed venture. MIMS spoke to SMCV’s Chief Executive Officer, Wilson Choo, to get his insights on the establishment of SMCV and his vision for SMCV in the short and long term.

Improving the patient experience at Bumrungrad International Hospital, Bangkok, Thailand

23 Jan 2020

Bumrungrad International Hospital was founded in 1980 and has since grown to become one of the most reputable hospitals in the region. The recipient of numerous international awards and accreditations, Bumrungrad International is one of the largest private hospitals in Southeast Asia, catering to over 1.1 million patients from over 190 countries annually.

In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.

Influenza as a public health threat: Prevalent, yet preventable

09 Jan 2020

In collaboration with the Malaysian Society of Infectious Diseases and Chemotherapy,Sanofi Pasteur Malaysia commemorated the launch of VaxigripTetra® by inviting three distinguished speakers to provide valuable insights into the prevalence of influenza and how vaccination can truly impact the health status of patients in general.

Personalizing treatment for chronic angina with concomitant diseases

23 Dec 2019

At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.

Extensive intraoperative peritoneal lavage of no benefit for gastric cancer patients

Pearl Toh, 28 Feb 2020

Not only does washing away free tumour cells in the peritoneum with extensive intraoperative peritoneal lavage (EIPL) during gastrectomy confer no survival benefit nor prevent disease recurrence compared with surgery alone, it may come with an increased risk of side effects, according to the phase III EXPEL* study presented at GICS 2020.

Nintedanib: A new player in bladder cancer?

Audrey Abella, 28 Feb 2020

The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).

Targeted combo therapies improve QoL, atop survival benefit for patients with BRAF+ CRC

Pearl Toh, 27 Feb 2020

In addition to survival benefit, the BEACON CRC trial has now shown that a targeted drug combination of encorafenib plus cetuximab with or without binimetinib led to longer maintenance of quality of life (QoL) for patients with BRAF V600E metastatic colorectal cancer (mCRC) compared with standard chemotherapy.

Improved pain response with cabazitaxel vs ARTA in mCRPC

Roshini Claire Anthony, 27 Feb 2020

In addition to extending survival, cabazitaxel also improves pain and quality of life (QoL) compared with abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), results from the phase III CARD* trial showed.

Betamethasone timing during late pregnancy does not affect neonatal outcomes

Tristan Manalac, 27 Feb 2020

The timing of betamethasone (BMZ) administration in pregnant women does not seem to differentially affect the suppression of the hypothalamic-pituitary-adrenal (HPA) axis and, in turn, has no apparent effect on neonatal outcomes, according to a study presented at recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).

Getting active during pregnancy leads to improved obstetric outcomes

Jairia Dela Cruz, 27 Feb 2020

Pregnant women may do well to exercise at an adequate amount, as it lowers the likelihood of adverse obstetric outcomes independent of blood pressure, according to a study presented at the Society for Maternal-Fetal Medicine (SMFM) 40th Annual Pregnancy Meeting.

Povidone iodine superior to chlorhexidine, saline preparation in reducing postpartum infections

Stephen Padilla, 26 Feb 2020

The use of povidone iodine (PI) is more effective than chlorhexidine gluconate (CHG) at reducing vaginal bacterial colony counts in pregnancy and appears to be a superior vaginal antiseptic for decreasing postpartum infections, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Medicine (SMFM 2020).

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!